Equities Analysts Issue Forecasts for Zoetis Q1 Earnings

Zoetis Inc. (NYSE:ZTS - Free Report) - Investment analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for Zoetis in a research report issued to clients and investors on Friday, January 31st. William Blair analyst B. Vazquez now anticipates that the company will earn $1.38 per share for the quarter, down from their prior estimate of $1.45. The consensus estimate for Zoetis' current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis' Q2 2025 earnings at $1.63 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $6.20 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.82 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.70 EPS and FY2026 earnings at $6.92 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business's revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.36 EPS.

ZTS has been the subject of several other reports. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $215.00.

Zoetis Price Performance

NYSE:ZTS traded up $0.30 during trading hours on Monday, reaching $172.24. 2,696,175 shares of the company were exchanged, compared to its average volume of 2,685,644. The stock's 50-day moving average is $169.48 and its 200-day moving average is $179.39. Zoetis has a twelve month low of $144.80 and a twelve month high of $200.53. The firm has a market cap of $77.71 billion, a PE ratio of 32.38, a price-to-earnings-growth ratio of 2.72 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. This is an increase from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio (DPR) is currently 37.59%.

Institutional Trading of Zoetis

Several institutional investors have recently made changes to their positions in the company. Mizuho Securities USA LLC increased its stake in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock worth $183,652,000 after purchasing an additional 937,700 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock valued at $144,917,000 after buying an additional 665,331 shares during the period. Nordea Investment Management AB raised its holdings in Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock valued at $336,266,000 after buying an additional 572,511 shares during the period. Finally, Holocene Advisors LP acquired a new position in Zoetis in the third quarter valued at about $110,809,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.